Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 2/2013

01-02-2013 | Basic Science

Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba Castellanii

Authors: Karim Makdoumi, Anders Bäckman, Jes Mortensen, Anders Magnuson, Sven Crafoord

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2013

Login to get access

Abstract

Purpose

To investigate whether ultraviolet light (UVA) at 365 nm can inhibit/eliminate Acanthamoeba growth and if riboflavin would potentiate such an association.

Methods

Acanthamoeba castellanii in a fluid medium with a concentration of approximately 1.7 × 104 protozoa/ml were prepared with (0.01 %) and without riboflavin. Exposure of UVA (dose 5.475 J/cm2) took place twice, with each illumination period followed by culturing of 10 μl in peptone yeast-extract glucose (PYG) medium for 7 days. Every suspension prepared had a non-exposed control solution. Determination of Acanthamoeba was conducted daily, by count in Burker chamber days 4 through 7 after exposure. Statistical analysis was done by repeated-measurement ANOVA and post-hoc analysis for unpaired samples.

Results

The exposure of ultraviolet light resulted in an inhibited growth of Acanthamoeba compared to the non-exposed solutions, with a statistically significant reduction over time (p = 0.0003). The addition of riboflavin did not amplify the effect, and there were no tendencies for an interaction effect between UVA and riboflavin.

Conclusions

The antiprotozoal effect of the UVA wavelength, utilized in CXL, is solely mediated by ultraviolet light, and riboflavin does not seem to amplify the antimicrobial efficacy.
Literature
1.
Yaeger RG (1996) Protozoa: structure, classification, growth, and development. In: Baron S (ed) Medical microbiology. The University of Texas Medical Branch at Galveston, Galveston
2.
Visvesvara GS, Moura H, Schuster FL (2007) Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 50:1–26PubMedCrossRef
3.
Marciano-Cabral F, Cabral G (2003) Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 16:273–307PubMedCrossRef
4.
Brindley N, Matin A, Khan NA (2009) Acanthamoeba castellanii: high antibody prevalence in racially and ethnically diverse populations. Exp Parasitol 121:254–256PubMedCrossRef
5.
Alizadeh H, Apte S, El-Agha MS, Li L, Hurt M, Howard K, Cavanagh HD, McCulley JP, Niederkorn JY (2001) Tear IgA and serum IgG antibodies against Acanthamoeba in patients with Acanthamoeba keratitis. Cornea 20:622–627PubMedCrossRef
6.
Khan NA (2006) Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol Rev 30:564–595PubMedCrossRef
7.
Kohsler M, Leitner B, Blaschitz M, Michel R, Aspock H, Walochnik J (2006) ITS1 sequence variabilities correlate with 18S rDNA sequence types in the genus Acanthamoeba (Protozoa: Amoebozoa). Parasitol Res 98:86–93PubMedCrossRef
8.
Nuprasert W, Putaporntip C, Pariyakanok L, Jongwutiwes S (2010) Identification of a novel t17 genotype of acanthamoeba from environmental isolates and t10 genotype causing keratitis in Thailand. J Clin Microbiol 48:4636–4640PubMedCrossRef
9.
Seal DV (2003) Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye (Lond) 17:893–905CrossRef
10.
Ku JY, Chan FM, Beckingsale P (2009) Acanthamoeba keratitis cluster: an increase in Acanthamoeba keratitis in Australia. Clin Experiment Ophthalmol 37:181–190PubMedCrossRef
11.
Thebpatiphat N, Hammersmith KM, Rocha FN, Rapuano CJ, Ayres BD, Laibson PR, Eagle RC Jr, Cohen EJ (2007) Acanthamoeba keratitis: a parasite on the rise. Cornea 26:701–706PubMedCrossRef
12.
Dart JK, Saw VP, Kilvington S (2009) Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol 148:487–499PubMedCrossRef
13.
Sun X, Zhang Y, Li R, Wang Z, Luo S, Gao M, Deng S, Chen W, Jin X (2006) Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology 113:412–416PubMedCrossRef
14.
Illingworth CD, Cook SD, Karabatsas CH, Easty DL (1995) Acanthamoeba keratitis: risk factors and outcome. Br J Ophthalmol 79:1078–1082PubMedCrossRef
15.
Butler TK, Males JJ, Robinson LP, Wechsler AW, Sutton GL, Cheng J, Taylor P, McClellan K (2005) Six-year review of Acanthamoeba keratitis in New South Wales, Australia: 1997–2002. Clin Experiment Ophthalmol 33:41–46PubMedCrossRef
16.
17.
18.
Iovieno A, Ledee DR, Miller D, Alfonso EC (2010) Detection of bacterial endosymbionts in clinical acanthamoeba isolates. Ophthalmology 117:445–452PubMedCrossRef
19.
Fritsche TR, Gautom RK, Seyedirashti S, Bergeron DL, Lindquist TD (1993) Occurrence of bacterial endosymbionts in Acanthamoeba spp. isolated from corneal and environmental specimens and contact lenses. J Clin Microbiol 31:1122–1126PubMed
20.
Horn M, Wagner M (2004) Bacterial endosymbionts of free-living amoebae. J Eukaryot Microbiol 51:509–514PubMedCrossRef
21.
Paterson GN, Rittig M, Siddiqui R, Khan NA (2011) Is Acanthamoeba pathogenicity associated with intracellular bacteria? Exp Parasitol 129:207–210PubMedCrossRef
22.
Martins SA, Combs JC, Noguera G, Camacho W, Wittmann P, Walther R, Cano M, Dick J, Behrens A (2008) Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci 49:3402–3408PubMedCrossRef
23.
Schrier A, Greebel G, Attia H, Trokel S, Smith EF (2009) In vitro antimicrobial efficacy of riboflavin and ultraviolet light on Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and Pseudomonas aeruginosa. J Refract Surg 25:S799–S802PubMedCrossRef
24.
Makdoumi K, Backman A, Mortensen J, Crafoord S (2010) Evaluation of antibacterial efficacy of photo-activated riboflavin using ultraviolet light (UVA). Graefes Arch Clin Exp Ophthalmol 248:207–212PubMedCrossRef
25.
Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T (2008) Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea 27:590–594PubMedCrossRef
26.
Micelli Ferrari T, Leozappa M, Lorusso M, Epifani E, Micelli Ferrari L (2009) Escherichia coli keratitis treated with ultraviolet A/riboflavin corneal cross-linking: a case report. Eur J Ophthalmol 19:295–297PubMed
27.
Moren H, Malmsjo M, Mortensen J, Ohrstrom A (2010) Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis. Cornea 29:102–104PubMedCrossRef
28.
Makdoumi K, Mortensen J, Crafoord S (2010) Infectious keratitis treated with corneal crosslinking. Cornea 29:1353–1358PubMedCrossRef
29.
Al-Sabai N, Koppen C, Tassignon MJ (2010) UVA/riboflavin crosslinking as treatment for corneal melting. Bull Soc Belge Ophtalmol 315:13–17PubMed
30.
Wollensak G, Spoerl E, Seiler T (2003) Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol 135:620–627PubMedCrossRef
31.
Sauer A, Letscher-Bru V, Speeg-Schatz C, Touboul D, Colin J, Candolfi E, Bourcier T (2010) In vitro efficacy of antifungal treatment using riboflavin/UV-A (365 nm) combination and amphotericin B. Invest Ophthalmol Vis Sci 51:3950–3953PubMedCrossRef
32.
Khan YA, Kashiwabuchi RT, Martins SA, Castro-Combs JM, Kalyani S, Stanley P, Flikier D, Behrens A (2011) Riboflavin and ultraviolet light A therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. Ophthalmology 118:324–331PubMedCrossRef
33.
Garduno-Vieyra L, Gonzalez-Sanchez CR, Hernandez-Da Mota SE (2011) Ultraviolet-a light and riboflavin therapy for acanthamoeba keratitis: a case report. Case Report Ophthalmol 2:291–295PubMed
34.
Hijnen WA, Beerendonk EF, Medema GJ (2006) Inactivation credit of UV radiation for viruses, bacteria and protozoan (oo)cysts in water: a review. Water Res 40:3–22PubMedCrossRef
35.
Sokmen M, Degerli S, Aslan A (2008) Photocatalytic disinfection of Giardia intestinalis and Acanthamoeba castellani cysts in water. Exp Parasitol 119:44–48PubMedCrossRef
36.
Del Buey MA, Cristobal JA, Casas P, Goni P, Clavel A, Minguez E, Lanchares E, Garcia A, Calvo B (2012) Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for acanthamoeba isolates. Am J Ophthalmol 153:399–404PubMedCrossRef
37.
Kashiwabuchi RT, Carvalho FR, Khan YA, de Freitas D, Foronda AS, Hirai FE, Campos MS, McDonnell PJ (2011) Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites. Invest Ophthalmol Vis Sci 52:9333–9338PubMedCrossRef
38.
Marschner S, Goodrich R (2011) Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 38:8–18PubMedCrossRef
39.
Mattana A, Biancu G, Alberti L, Accardo A, Delogu G, Fiori PL, Cappuccinelli P (2004) In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii. Antimicrob Agents Chemother 48:4520–4527PubMedCrossRef
40.
Cariello AJ, de Souza GF, Foronda AS, Yu MC, Hofling-Lima AL, de Oliveira MG (2010) In vitro amoebicidal activity of S-nitrosoglutathione and S-nitroso-N-acetylcysteine against trophozoites of Acanthamoeba castellanii. J Antimicrob Chemother 65:588–591PubMedCrossRef
41.
Beattie TK, Seal DV, Tomlinson A, McFadyen AK, Grimason AM (2003) Determination of amoebicidal activities of multipurpose contact lens solutions by using a most probable number enumeration technique. J Clin Microbiol 41:2992–3000PubMedCrossRef
42.
Oldenburg CE, Keenan JD, Cevallos V, Chan MF, Acharya NR, Gaynor BD, McLeod SD, Esterberg EJ, Porco TC, Lietman TM (2011) Microbiological cure times in acanthamoeba keratitis. Eye (Lond) 25:1155–1160CrossRef
Metadata
Title
Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba Castellanii
Authors
Karim Makdoumi
Anders Bäckman
Jes Mortensen
Anders Magnuson
Sven Crafoord
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2013
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-012-2176-4

Other articles of this Issue 2/2013

Graefe's Archive for Clinical and Experimental Ophthalmology 2/2013 Go to the issue

Cornea

Corneal biochemical features of patients with vernal keratoconjunctivitis

Retinal Disorders

Analysis of factors correlated with the development of pseudophakic retinal detachment - a long-term study in a single medical center

Neurophthalmology

Spectral-domain optical coherence tomography detects optic atrophy due to optic tract syndrome

Refractive Surgery

A comparison between Goldmann applanation tonometry and dynamic contour tonometry after photorefractive keratectomy

Retinal Disorders

Glial proliferation after vitrectomy for a macular hole: a spectral domain optical coherence tomography study

Retinal Disorders

Pain assessment in premature infants treated with intravitreal antiangiogenic therapy for retinopathy of prematurity under topical anesthesia